Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Source URL: https://qa1.novartis.us/us-en/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer-0
List of links present in page
- https://qa1.novartis.us/us-en/us-en/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer-0